Fig. 4.
Pharmacokinetics of 2-amino-6-trifluoromethylthio-benzothiazole (SKA-19). (a) Total SKA-19 plasma concentrations (mean ± SD) following intravenous administration of 10 mg/kg in CremophorEL (Sigma-Aldrich, St. Louis, MO, USA)/phosphate-buffered saline to male Sprague–Dawley rats (n = 3). The inset shows the same data on a log scale. The data were best fitted as biexponential decay and with a quick distribution into tissue followed by elimination (t1/2 = 2.16 ± 0.023 h). (b) SKA-19 plasma concentrations following oral gavage application at 10 mg/kg in solution (n = 3) or as a methylcellulose suspension (n = 3). (c) Plasma concentrations following intraperitoneal (i.p.) application at 10 and 30 mg/kg (n = 3). (d) Tissue concentrations 2 h after i.p. administration of SKA-19 and riluzole at 10 mg/kg (n = 3)